BGLC

Business Context and Reporting Period

Company: BioNexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: BGLC operates three primary segments: genomic screening services (MRNA Scientific), industrial chemical trading (Chemrex), and investment holding. The company is currently transitioning its Chemrex subsidiary from chemical trading to a biotechnology-focused Contract Development and Manufacturing Organization (CDMO). Additionally, the Board has approved an Ethereum-focused treasury strategy, though no digital assets were held as of the reporting date.

Key Financial Metrics (Nine Months Ended Sept 30, 2025)

Material Changes vs. Prior Period

• Revenue: Decreased 0.7% to $6.94 million compared to $6.99 million in the prior year period. The decline was driven by lower sales volume in the industrial chemicals segment, partially offset by a slight increase in genomic screening services.
• Profitability: Net loss widened to $1.95 million from $1.25 million in the prior year. This was primarily due to a significant decrease in "Other Income" (down 70.8%) caused by the absence of fair value gains on equity securities and lower reversals of expected credit losses.
• Operating Expenses: Total operating expenses decreased slightly by 3.0% to $3.43 million. This reduction was driven by lower General and Administrative expenses and reduced fair value losses on investments, partially offset by higher Sales and Marketing expenses and increased provisions for expected credit losses.
• Cash Flow: Net cash used in operating activities increased to $2.80 million from $2.31 million. However, investing activities generated a net cash inflow of $0.95 million, primarily from the disposal of equity securities ($1.02 million).
• Balance Sheet: Total assets decreased by approximately 27% to $7.62 million, largely due to the disposal of equity investments and foreign currency translation adjustments.

Guidance, Outlook, and Risks

Management Commentary and Strategic Initiatives

• CDMO Transition: Chemrex is actively transitioning to a CDMO model, with up to MYR 10 million authorized for facility upgrades and GMP certification. Management expects this to shift revenue mix toward higher-margin biotech contracts by 2026.
• Strategic Partnerships:
  • Fidelion Diagnostics: Entered a non-binding term sheet for a cross-equity alliance and exclusive commercialization rights for the VitaGuard™ MRD platform in Southeast Asia. A Share Subscription and Shareholders' Agreement (SSSA) was subsequently filed, subject to conditions precedent.
  • BirchBioMed: Entered a non-binding term sheet to lead a $10 million financing round and collaborate on commercializing regenerative treatments in Southeast Asia.
• Capital Markets: Filed a Form S-3 registration statement to register up to $100 million of securities and entered an Equity Distribution Agreement (ATM Program) with Maxim Group LLC for up to $20 million in at-the-market offerings.
• Reverse Stock Split: A 1-for-10 reverse stock split was effected on April 7, 2025, to maintain Nasdaq compliance.

Risks and Contingencies

• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to a significant deficiency at the Chemrex subsidiary regarding documentation standards and delegation of authority. A remediation plan is underway.
• Transaction Risk: The Fidelion and BirchBioMed transactions are non-binding or subject to conditions; there is no assurance they will close.
• Cryptocurrency Volatility: The approved Ethereum treasury strategy exposes the company to market volatility and regulatory risks, though no assets were held at period end.
• Going Concern: While management believes liquidity is sufficient for 12 months, the company has an accumulated deficit of $5.39 million and negative operating cash flows.

Investor Verification Checklist

• Internal Control Remediation: Verify the progress of the remediation plan for the significant deficiency identified at the Chemrex subsidiary.
• Transaction Closing: Monitor the execution of definitive agreements for the Fidelion Diagnostics and BirchBioMed partnerships, as current term sheets are non-binding.
• ATM Program Utilization: Track the effectiveness of the S-3 filing and any share issuances under the $20 million ATM program with Maxim Group.
• CDMO Progress: Assess milestones for Chemrex's transition to a CDMO, specifically facility upgrades and GMP certification status.
• Credit Risk: Review the increasing provision for expected credit losses ($215,942 for the nine months), indicating potential customer payment issues in the chemical trading segment.